Niesvizky, R., & Raab, M. (2015). Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leukemia and lymphoma, 56(12), .
Chicago-Zitierstil (17. Ausg.)Niesvizky, Ruben, und Marc-Steffen Raab. "Phase 1/2 Study of Cyclin-dependent Kinase (CDK)4/6 Inhibitor Palbociclib (PD-0332991) with Bortezomib and Dexamethasone in Relapsed/refractory Multiple Myeloma." Leukemia and Lymphoma 56, no. 12 (2015).
MLA-Zitierstil (9. Ausg.)Niesvizky, Ruben, und Marc-Steffen Raab. "Phase 1/2 Study of Cyclin-dependent Kinase (CDK)4/6 Inhibitor Palbociclib (PD-0332991) with Bortezomib and Dexamethasone in Relapsed/refractory Multiple Myeloma." Leukemia and Lymphoma, vol. 56, no. 12, 2015.